Noe MH, Wan MT, Shin DB, et al. - Because data on the impact of narrowband ultraviolet B phototherapy on patient-reported health-related quality of life measures are limited, researchers assessed the impact of adalimumab and phototherapy on health-related quality of life. From a multicenter, randomized, placebo-controlled trial, patient-reported outcomes were examined. Every 4 weeks, the Dermatology Life Quality Index and EQ-5D-3L were assessed. Participants in the study were 97 patients (mean age was 43.5 years). Investigators found that phototherapy and adalimumab in patients with psoriasis improve both the skin-related quality of life and overall health-related quality of life vs placebo. However, phototherapy-treated patients accomplished more improvements in overall health-related quality of life vs adalimumab-treated patients.